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Re: Views of American
Oncologists About the Purposes
of Clinical Trials
In a recent article in the Journal, Joffe
and Weeks (1) reported that most pedi-
atric oncologists offered their patients
the opportunity to enroll in trials to en-
sure that their patients received “state-
of-the-art” therapy and that nearly 40%
of responding pediatricians “reported
that trials exist primarily to ensure state-
of-the-art therapy for the participants
themselves.” In an accompanying edito-
rial, Miller (2) worried that a substantial
proportion of pediatric oncologists
might misconceive the purpose of clini-
cal trials, thereby creating a “therapeutic
misconception” for the children and
families who agree to trial participation,
as well as for the oncology teams treat-
ing those children.
Pediatric cancer specialists in North
America have cooperatively designed
and conducted sequential, randomized
phase III clinical trials for more than
four decades to use evidence-based in-
formation to refine the treatment of chil-
dren with cancer. The state-of-the-art
treatment for a child with cancer derives
from the best therapy identified in prior
clinical trials, and this best-available
treatment serves as the standard arm of
subsequent phase III clinical trials.
Thus, the standard arms of clinical re-
search protocols serve as de facto prac-
tice guidelines, and newly diagnosed
children can receive this state-of-the-art
standard therapy whether or not they en-
roll in a clinical research trial.
The national pediatric phase III can-
cer therapy studies are reviewed by mul-
tiple panels of childhood cancer experts
to ensure that all treatment arms comply
with current best-available therapy.
Once a trial is initiated, data monitoring
committees are charged with stopping
the study if sufficient evidence develops
to demonstrate that treatment outcome
or toxicity no longer conform to best-
available therapy. By investigating incre-
mental modifications of best-available
therapy in sequential phase III studies,
pediatric oncology specialists have
learned to employ radiotherapy, surgery,
and a limited number of common che-
motherapy agents in a risk-based man-
ner, thereby generating steady improve-
ments in patient outcome. For example,
5-year survival for children with acute
lymphoblastic leukemia, which was less
than 5% in the early 1960s, increased to
approximately 50% in the mid-1970s
and to 85% by the mid-1990s.
The academic environment in which
most pediatric oncologists practice al-
lows physician–investigators to pursue
clinical research as a means to improve
treatments. However, this pursuit sets up
a potential conflict between the practi-
tioner’s dual roles as clinician and in-
vestigator. In recognition of this poten-
tial conflict, the Children’s Oncology
Group has studied the informed-consent
process (3,4) and is working to clarify
and improve both the decision-making
process that families encounter and the
information provided by the pediatric
oncology team. Efforts to discriminate
between the experimental and the stan-
dard treatment components of a proto-
col’s diagnostic and therapy require-
ments have been augmented. The goal
of these efforts is to help families and
their physicians better understand how
research questions affect potential study
participants and better determine wheth-
er study enrollment is the most appro-
priate choice for a particular child.
Pediatric cancer specialists are com-
mitted to clinical research because they
understand that well-designed clinical
trials with appropriate safeguards are the
best path to identifying and delivering
more effective therapies, while at the
same time providing treatment that is
consistent with current best-available
therapy. Society, and especially children
diagnosed with cancer, continues to be
well served by the dedicated clinical
care and clinical research efforts of the
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health care professionals specializing in
pediatric oncology.
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RESPONSE
We welcome the thoughtful corre-
spondence by Anderson et al. about our
recent paper on American oncologists’
views of clinical trials (1), and we sec-
ond their comments. These investigators
correctly highlight the exemplary work
of the pediatric oncology community
over the past few decades in improving
outcomes for children with cancer. The
clinical trials program in pediatric on-
cology, which has served as the founda-
tion for these advances, constitutes an
international model for sustained and
systematic improvement in the state of
the clinical art (2).
We particularly appreciate the au-
thors’ characterization of the standard
arm of a randomized phase III trial as
state-of-the-art treatment that is avail-
able to patients whether or not they en-
roll in a trial. This characterization,
which implies that the experimental arm
represents a (generally reasonable) de-
viation from the standard of care, brings
much-needed clarity to our thinking
about clinical research.
The data we reported suggest that the
ethical challenges inherent in all clinical
research may be particularly acute in pe-
diatric oncology, perhaps because of the
unparalleled integration of trials into the
routine care of pediatric cancer patients.
To its credit, the pediatric oncology
community has engaged in valuable dia-
logue and research about the complexi-
ties of conducting clinical trials among
children with cancer (3–6). We join
Anderson et al. in underscoring the fun-
damentally ethical nature of this re-
search enterprise and salute the dedi-
cation of all who contribute to this
important effort.
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